Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability (original) (raw)

• Vousden, K. H. p53: death star. Cell 103, 691–694 (2000).
  Article CAS Google Scholar
• Hollstein, M. et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22, 3551–3555 (1994).
  CAS PubMed PubMed Central Google Scholar
• Bargonetti, J. & Manfredi, J. J. Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. 14, 86–91 (2002).
  Article CAS Google Scholar
• Bode, A. M. & Dong, Z. Post-translational modification of p53 in tumorigenesis. Nature Rev. Cancer 4, 793–805 (2004).
  Article CAS Google Scholar
• Shieh, S. Y., Taya, Y. & Prives, C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser 20, requires tetramerization. EMBO J. 18, 1815–1823 (1999).
  Article CAS Google Scholar
• Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y. & Prives, C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14, 289–300 (2000).
  CAS PubMed PubMed Central Google Scholar
• Chehab, N. H., Malikzay, A., Appel, M. & Halazonetis, T. D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14, 278–288 (2000).
  CAS PubMed PubMed Central Google Scholar
• Hirao, A. et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287, 1824–1827 (2000).
  Article CAS Google Scholar
• Sakaguchi, K. et al. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J. Biol. Chem. 275, 9278–9283 (2000).
  Article CAS Google Scholar
• Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. & Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945–8951 (2000).
  Article CAS Google Scholar
• Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296–299 (1997).
  Article CAS Google Scholar
• Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299–303 (1997).
  Article CAS Google Scholar
• Barak, Y., Juven, T., Haffner, R. & Oren, M. Mdm2 expression is induced by wild type p53 activity. EMBO J. 12, 461–468 (1993).
  Article CAS Google Scholar
• Bech-Otschir, D. et al. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J. 20, 1630–1639 (2001).
  Article CAS Google Scholar
• Ito, A. et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20, 1331–1340 (2001).
  Article CAS Google Scholar
• Rodriguez, M. S., Desterro, J. M., Lain, S., Lane, D. P. & Hay, R. T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 20, 8458–8467 (2000).
  Article CAS Google Scholar
• Rodriguez, M. S. et al. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18, 6455–6461 (1999).
  Article CAS Google Scholar
• Gostissa, M. et al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18, 6462–6471 (1999).
  Article CAS Google Scholar
• Fuchs, S. Y., Lee, C. G., Pan, Z. Q. & Ronai, Z. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 110, 531 (2002).
  Article Google Scholar
• Kearse, K. P. & Hart, G. W. Lymphocyte activation induces rapid changes in nuclear and cytoplasmic glycoproteins. Proc. Natl Acad. Sci. U.S.A. 88, 1701–1705 (1991).
  Article CAS Google Scholar
• Wells, L., Vosseller, K. & Hart, G. W. Glycosylation of nucleocytoplasmic proteins: signal transduction and _O_-GlcNAc. Science 291, 2376–2378 (2001).
  Article CAS Google Scholar
• Hanover, J. A. Glycan-dependent signaling: _O_-linked N-acetylglucosamine. FASEB J. 15, 1865–1876 (2001).
  Article CAS Google Scholar
• Shaw, P., Freeman, J., Bovey, R. & Iggo, R. Regulation of specific DNA binding by p53: evidence for a role for _O_-glycosylation and charged residues at the carboxy-terminus. Oncogene 12, 921–930 (1996).
  CAS PubMed Google Scholar
• Toleman, C., Paterson, A. J., Shin, R. & Kudlow, J. E. Streptozotocin inhibits _O_-GlcNAcase via the production of a transition state analog. Biochem. Biophys. Res. Commun. 340, 526–534 (2006).
  Article CAS Google Scholar
• Wells, L. et al. Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol. Cell. Proteomics 1, 791–804 (2002).
  Article CAS Google Scholar
• Chalkley, R. J. & Burlingame, A. L. Identification of novel sites of _O_-N-acetylglucosamine modification of serum response factor using quadrupole time-of-flight mass spectrometry. Mol. Cell. Proteomics 2, 182–190 (2003).
  Article CAS Google Scholar
• Lowe, S. W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807–810 (1994).
  Article CAS Google Scholar
• Kang, H. T., Ju, J. W., Cho, J. W. & Hwang, E. S. Down-regulation of Sp1 activity through modulation of _O_-glycosylation by treatment with a low glucose mimetic, 2-deoxyglucose. J. Biol. Chem. 278, 51223–51231 (2003).
  Article CAS Google Scholar
• Konrad, R. J., Mikolaenko, I., Tolar, J. F., Liu, K. & Kudlow, J. E. The potential mechanism of the diabetogenic action of streptozotocin: inhibition of pancreatic β-cell _O_-GlcNAc-selective N-acetyl-β-D-glucosaminidase. Biochem. J. 356, 31–41 (2001).
  Article CAS Google Scholar
• Bech-Otschir, D., Seeger, M. & Dubiel, W. The COP9 signalosome: at the interface between signal transduction and ubiquitin-dependent proteolysis. J. Cell Sci. 115, 467–473 (2002).
  CAS PubMed Google Scholar
• Comer, F. I. & Hart, G. W. _O_-Glycosylation of nuclear and cytosolic proteins. Dynamic interplay between _O_-GlcNAc and _O_-phosphate. J. Biol. Chem. 275, 29179–29182 (2000).
  Article CAS Google Scholar
• Clore, G. M. et al. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nature Struct. Biol. 2, 321–333 (1995).
  Article CAS Google Scholar
• Kawaguchi, T. et al. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 24, 6976–6981 (2005).
  Article CAS Google Scholar
• Saito, S. et al. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J. Biol. Chem. 278, 37536–37544 (2003).
  Article CAS Google Scholar
• Prives, C., & Hall, P. A. The p53 pathway. J. Pathol. 187, 112–126 (1999).
  Article CAS Google Scholar
• Schon, O., Friedler, A., Bycroft, M., Freund, S. M., & Fersht, A. R. Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323, 491–501 (2002).
  Article CAS Google Scholar
• Canadillas, J. M. et al. Solution structure of p53 core domain: structural basis for its instability. Proc. Natl Acad. Sci. USA 103, 2109–2114 (2006).
  Article Google Scholar
• Cheng, X., Cole, R. N., Zaia, J. & Hart, G. W. Alternative _O_-glycosylation/_O_-phosphorylation of the murine estrogen receptor β. Biochemistry 39, 11609–11620 (2000).
  Article CAS Google Scholar
• Cheng, X. & Hart, G. W. Alternative _O_-glycosylation/_O_-phosphorylation of serine-16 in murine estrogen receptor β: post-translational regulation of turnover and transactivation activity. J. Biol. Chem. 276, 10570–10575 (2001).
  Article CAS Google Scholar
• Gao, Y., Parker, G. J. & Hart, G. W. Streptozotocin-induced β-cell death is independent of its inhibition of _O_-GlcNAcase in pancreatic Min6 cells. Arch. Biochem. Biophys. 383, 296–302 (2000).
  Article CAS Google Scholar
• Haltiwanger, R. S., Grove, K. & Philipsberg, G. A. Modulation of _O_-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide _O_-GlcNAc-β-N-acetylglucosaminidase inhibitor _O_-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate. J. Biol. Chem. 273, 3611–3617 (1998).
  Article CAS Google Scholar
• Zhang, F. et al. _O_-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115, 715–725 (2003).
  Article CAS Google Scholar
• Liu, K. et al. Accumulation of protein _O_-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high _O_-GlcNAc metabolism. J. Neurochem. 89, 1044–1055 (2004).
  Article CAS Google Scholar
• Fiordaliso, F. et al. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 50, 2363–2375 (2001).
  Article CAS Google Scholar
• Licitra, L. et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J. Clin. Oncol. 22, 4901–4906 (2004).
  Article CAS Google Scholar
• Hsu, C. H., Yang, S. A., Wang, J. Y., Yu, H. S. & Lin, S. R. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br. J. Cancer 80, 1080–1086 (1999).
  Article CAS Google Scholar
• Morgan, S. E. et al. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells. Oncogene 19, 5010–5019 (2000).
  Article CAS Google Scholar
• Ryu, J. et al. Intracellular delivery of p53 fused to the basic domain of HIV-1 tat. Mol. Cells 17, 353–359 (2004).
  CAS PubMed Google Scholar
• Wang, W., Takimoto, R., Rastinejad, F. & El-Deiry, W. S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell. Biol. 23, 2171–2181 (2003).
  Article CAS Google Scholar